Recombinant human TSH (rhTSH, Thyrogen®), by activating the TSH receptor (TSHR), has been used to great advantage in the initial treatment and follow-up of patients with thyroid cancer, and to a more limited extent as an adjunct in the treatment of patients with nodular goiter (1–4). Here, TSHR is linked to thyroid cancer.